EVOLUS, INC. Share-based Payment Arrangement, Expensed and Capitalized, Amount
EVOLUS, INC. (EOLS) reported Share-based Payment Arrangement, Expensed and Capitalized, Amount of $5.64 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Notes › Share-Based Payment Arrangement › Share-Based Payment Arrangement, Expensed and Capitalized, Amount
us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1 · last filed 2026-08-05
- EVOLUS, INC. share-based payment arrangement, expensed and capitalized, amount for the quarter ending 2026-06-30 was $5.64M, a 24.63% increase year-over-year.
- EVOLUS, INC. share-based payment arrangement, expensed and capitalized, amount for the quarter ending 2026-03-31 was $5.12M, a 14.16% decline year-over-year.
- EVOLUS, INC. share-based payment arrangement, expensed and capitalized, amount for the quarter ending 2025-12-31 was $5.16M, a 15.76% decline year-over-year.
- EVOLUS, INC. share-based payment arrangement, expensed and capitalized, amount for the quarter ending 2025-09-30 was $5.15M, a 1.83% decline year-over-year.
- EVOLUS, INC. share-based payment arrangement, expensed and capitalized, amount for fiscal 2025 was $20.80M, a 6.55% decline from fiscal 2024.
- EVOLUS, INC. share-based payment arrangement, expensed and capitalized, amount for fiscal 2024 was $22.25M, a 35.22% increase from fiscal 2023.
- EVOLUS, INC. share-based payment arrangement, expensed and capitalized, amount for fiscal 2023 was $16.46M.
| Period end | Share-based Payment Arrangement, Expensed and Capitalized, Amount 3 month | Share-based Payment Arrangement, Expensed and Capitalized, Amount 6 month | Share-based Payment Arrangement, Expensed and Capitalized, Amount 9 month | Share-based Payment Arrangement, Expensed and Capitalized, Amount 12 month |
|---|---|---|---|---|
| 2026-06-30 | $5.64M 10-Q · filed 2026-08-05 | $10.76M 10-Q · filed 2026-08-05 | $15.92M derived: sum of 3 quarters · filed 2026-08-05 | $21.07M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $5.12M 10-Q · filed 2026-05-04 | $10.28M derived: sum of 2 quarters · filed 2026-05-04 | $15.43M derived: sum of 3 quarters · filed 2026-05-04 | $19.95M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $5.16M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $10.31M derived: sum of 2 quarters · filed 2026-03-03 | $14.83M derived: sum of 3 quarters · filed 2026-08-05 | $20.80M 10-K · filed 2026-03-03 |
| 2025-09-30 | $5.15M 10-Q · filed 2025-11-05 | $9.67M derived: sum of 2 quarters · filed 2026-08-05 | $15.64M 10-Q · filed 2025-11-05 | $21.76M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $4.52M 10-Q · filed 2026-08-05 | $10.49M 10-Q · filed 2026-08-05 | $16.61M derived: sum of 3 quarters · filed 2026-08-05 | $21.86M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $5.97M 10-Q · filed 2026-05-04 | $12.09M derived: sum of 2 quarters · filed 2026-05-04 | $17.33M derived: sum of 3 quarters · filed 2026-05-04 | $23.13M derived: sum of 4 quarters · filed 2026-05-04 |
| 2024-12-31 | $6.12M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $11.37M derived: sum of 2 quarters · filed 2026-03-03 | $17.16M derived: sum of 3 quarters · filed 2026-03-03 | $22.25M 10-K · filed 2026-03-03 |
| 2024-09-30 | $5.25M 10-Q · filed 2025-11-05 | $11.04M derived: sum of 2 quarters · filed 2025-11-05 | $16.13M 10-Q · filed 2025-11-05 | |
| 2024-06-30 | $5.79M 10-Q · filed 2025-08-05 | $10.88M 10-Q · filed 2025-08-05 | ||
| 2023-12-31 | $16.46M 10-K · filed 2026-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |